Atezolizumab、贝伐珠单抗、卡铂和紫杉醇 (ABCP) 联合疗法对接受酪氨酸激酶抑制剂 (TKI) 治疗后出现表皮生长因子受体 (EGFR) 突变的特定非鳞状非小细胞肺癌 (NSCLC) 患者具有潜在疗效） 治疗。然而，关于 ABCP 治疗作为 EGFR-TKI 使用的主要结局的有效性的研究还很缺乏。对 24 例接受一种或多种治疗的 IV 期 EGFR 阳性非鳞状 NSCLC 患者进行了单中心回顾性分析。更多线的 EGFR-TKI 治疗，并随后在 2019 年 4 月 1 日至 2023 年 4 月 30 日期间开始 ABCP 治疗。这项研究评估了与 ABCP 治疗相关的总生存期和无进展生存期，并根据EGFR 亚组。队列的平均年龄为 65 ± 9 岁，其中 14 名女性 (58%)。 24 名患者中有 13 名 (54%) 的体能状态 (PS) 为 0，24 名患者中有 11 名 (46%) 为 1。十三名（54%）患者有吸烟史。腺癌组织学在所有病例中都很常见。 EGFR 突变包括 14 名患者 (58%) 的 Ex19del 和 10 名患者 (42%) 的 L858R。 ABCP 治疗开始时，3 例 (13%) 出现明显肝转移，8 例 (33%) 出现脑转移。程序性死亡配体 1 (22C3) 表达水平各不相同，分别在 5 例、11 例和 5 例中观察到 <1%、1-49% 和 ≥50%，而 3 例数据缺失。中位随访时间为 14.1 个月，中位总生存期估计为 23.6 个月（95% CI：14.5 个月 - 未达到），中位无进展生存期为 5.6 个月（95% CI：4.9-11.5 个月）。与 EGFR Ex19del 突变相比，EGFR L858R 突变在总体生存方面表现出有利的趋势（未评估与 23.6 个月相比）。对于 EGFR 阳性非鳞状 NSCLC 的 ABCP 治疗是一种有前途的选择，类似于无免疫检查点抑制剂的铂类药物。为基础的联合治疗。因此，有必要进行前瞻性试验来确认这些治疗的疗效。版权所有 © 2024，Kobayashi 等人。

Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) combination therapy has a potential efficacy in a specific subset of non-squamous non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations following tyrosine kinase inhibitor (TKI) treatment. However, there is a dearth of investigations on the effectiveness of ABCP therapy as the primary outcome of EGFR-TKI use.A single-center retrospective analysis was performed on 24 cases of stage IV EGFR-positive non-squamous NSCLC patients who received one or more lines of EGFR-TKI therapy and subsequently initiated ABCP therapy within the timeframe of April 1, 2019, to April 30, 2023. This study assessed overall survival and progression-free survival associated with ABCP therapy, further analyzing the overall survival data based on EGFR subgroups.The mean age of the cohort was 65 ± 9 years with 14 females (58%). The performance status (PS) was recorded as 0 in 13 out of 24 patients (54%) and 1 in 11 out of 24 patients (46%). Thirteen (54%) patients had a history of smoking. Adenocarcinoma histology was prevalent in all cases. The EGFR mutations included Ex19del in 14 patients (58%) and L858R in 10 (42%) patients. At ABCP therapy initiation, liver metastases were evident in three cases (13%) and brain metastases in eight (33%). Programmed death ligand 1 (22C3) expression levels varied, with <1%, 1-49%, and ≥50% observed in five, 11, and five cases, respectively, while data were missing for three cases. The median follow-up duration was 14.1 months, with median overall survival estimated at 23.6 months (95% CI: 14.5 months - not reached) and median progression-free survival at 5.6 months (95% CI: 4.9-11.5 months). The EGFR L858R mutation showed a favorable trend in overall survival compared with the EGFR Ex19del mutation (not evaluated vs. 23.6 months).ABCP therapy for EGFR-positive non-squamous NSCLC is a promising option, similar to immune checkpoint inhibitor-free platinum-based combination therapy. Therefore, prospective trials are necessary to confirm the efficacy of these treatments.Copyright © 2024, Kobayashi et al.